Table 2: Studies of switch towards more lipid-friendly antiretroviral regimens and variations in total and fractionated cholesterol and triglyceride blood levels.

AuthorYearStudy drugSwitched drugDesignPatients F-up (wks)∆ TC (mmol/L)∆HDL (mmol/L)∆LDL (mmol/L)∆ TG (mmol/L)

Negredo [34]2002Nevirapine EfavirenzPIsRandomized7748
only Nev.
NANA
only Nev.
Petit [35]2004NevirapinePIsObservational5524NA
NA
Ward [36]2006NevirapineEfavirenzRetrospective40106



Parienti [37]2007NevirapineEfavirenzRandomized3652NA NANA
Gonzalez-Tome [38]2008NevirapinePIsPediatric, case-series752

stableNA
Katlama [39]2003AbacavirPIsRandomized20948 NANA
Keiser [40]2005AbacavirPIsRandomized10428
NA

Soriano [41]2005 PIsRandomized18948
NANA
Gatell [42]2007Atazanavir/rPIsRandomized41948 NA
Mallolas [44]2009Atazanavir/rPIsRandomized24848
NANA
Llibre [43]2006TDFStavudineRetrospective35248
NA

Schewe [44]2006TDFStavudineRetrospective66130
NANANA
Madruga [45]2007TDFStavudineRandomized85144
NANA
Valantin [46]2010TDF/FTCNRTIsRandomized9112NANA

Eron [41]2010RaltegravirLopinavir/rRandomized70712 %
NA %
%

49 patients switched to unboosted atazanavir, 53 to atazanavir/r.